As America desperately waited for its influenza vaccines, Chiron
had to deal with major quality control issues between July and
October 2005 at its troubled vaccine manufacturing plant in
Liverpool according to a US Food and Drug...
US biotechnology company Chiron has rejected a takeover offer from
Swiss drugmaker Novartis, saying the latter's $40 a share offer
does not pass muster.
Novartis has offered to buy the remaining shares it does not
already own in US headquartered Chiron for $4.5 billion, laying to
rest speculation in the marketplace that it had been eyeing up
Germany's Schering AG.
US drugmaker Chiron is facing a significant shortfall in the volume
of influenza vaccine it will be able to ship to markets outside the
US as a result of sterility problems uncovered at another of its
manufacturing plants, reports...
The UK regulatory authorities have cleared Chiron to resume
production of its influenza vaccine Fluvirin at its facility in
Liverpool, lifting a ban imposed in October because of
contamination problems at the plant.
Chiron said yesterday that the UK and US regulatory authorities are
expected to conduct a series of inspections of its manufacturing
facility in Liverpool, which was forced to cease production of
influenza vaccines last year, leading...
The UK suspension preventing Chiron's export of Fluvirin took
another twist yesterday after the biotech company became the
subject of a US federal investigation over its reporting of the
problems with the flu vaccine.
Chiron's headquarters is hit by two homemade bombs, with an animal
rights group claiming responsibility. The blasts caused no
casualties and only minor damage to property, but represent an
alarming escalation in the tactics used...
Chiron's has completed its acquisition of UK vaccine and drug
delivery specialist PowderJect, making it the second-largest
manufacturer of flu vaccines worldwide.